I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Lung Cancer

Lung Cancer

Lung cancer is the most common cancer in the world but still remains a challenge both in the clinical and research settings.

From studying the biology of lung cancer cells in the lab to leading clinical trials testing cutting-edge treatments, Roche is committed to addressing the medical need for therapies that extend patients’ lives.

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Mar 27 / Roche and Genentech
A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Efficacy and safety from the phase II BO44178 study of tobemstomig plus platinum-based chemotherapy versus pembrolizumab plus chemotherapy in patients with untreated locally advanced or metastatic NSCLC.
Oncology Lung Cancer ELCC-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 24 / Roche and Genentech
IMpower010: Digital pathology (DP) vs manual SP263 PD-L1 tumour cell (TC) scoring on whole imaging slides from patients (pts) with stage II-IIIA PD-L1 TC >=50% NSCLC
PD-L1 expression is predictive of anti–PD-1/–PD-L1 therapy benefit, but intratumoral heterogeneity, interobserver variability, multiple assays and scoring systems make its reliable evaluation problematic. A clone-agnostic artificial intelligence (AI) model for AI-based measurement of PD-L1 (AIM-PD-L1) was developed to address this challenge. In this exploratory analysis, we compared manual and AIM-PD-L1 scoring of SP263-stained tumour cell (TC) PD-L1 to assess the model’s ability to identify patients with stage II-IIIA PD-L1 TC ≥50% NSCLC from IMpower010 who can benefit from atezolizumab (NCT02486718) in an unbiased, automated manner.
Oncology Lung Cancer ELCC-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 6 / Roche and Genentech
Third OS interim analysis from BEAT-SC: Addition of bevacizumab to atezolizumab & chemotherapy in patients with ES-SCLC
The Phase III BEAT-SC study is evaluating bevacizumab + atezolizumab and carboplatin/cisplatin and etoposide (ACE) vs placebo + ACE in patients with untreated ES-SCLC from Japan and China. This presentation reports the third OS interim analysis and additional updated clinical data from BEAT-SC.
Oncology Lung Cancer JSMO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 6 / Roche and Genentech
Resistance mechanisms and efficacy of first-line alectinib in patients with ALK+ non-small cell lung cancer
ALCURE is a real-world, observational, multi-center study exploring resistance mechanisms to first-line alectinib, prognostic factors of the efficacy of alectinib and optimal treatment sequencing in patients with advanced ALK-positive NSCLC. This oral presentation presents efficacy data with first-line alectinib and resistance mechanisms to alectinib from the second interim analysis of the ALCURE study.
Oncology Lung Cancer JSMO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 6 / Roche and Genentech
Pharmacokinetics and safety of adjuvant alectinib in Japanese patients (pts) from ALINA with resected ALK-positive NSCLC
ALINA: Subgroup analysis investigating the pharmacokinetics and safety of adjuvant alectinib in Japanese patients with resectable stage IB-IIIA (UICC/AJCC 7th edition) ALK-positive NSCLC.
Oncology Lung Cancer JSMO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 3 / Roche and Genentech
HORIZON-01: a phase I-III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC)
HORIZON-01 is an ongoing phase I–III, open-label, randomised platform study, evaluating the efficacy and safety of multiple targeted therapies (alectinib and entrectinib▼) compared with durvalumab, following concurrent radiotherapy (CRT) in patients with locally advanced, unresectable, stage III NSCLC. This trial-in-progress poster presents the trial design, key patient eligibility and study endpoints.
Oncology Lung Cancer BTOG-2025
Treatment management
  • Lung Cancer
  • More
9 results

Sign up or login to unlock the full suite of MEDICALLY features
Sep 14 / Roche and Genentech
WCLC-2023-Meet the expert slides-screening and biomarker testing in resectable NSCLC
Slides from the early-stage NSCLC meet-the-expert session at WCLC 2023. Pan-Chyr Yang and Eran Choman cover the improved efficiency with LungFlag versus opportunistic selection in a theoretical East Asian lung cancer screening program, and then Jay M. Lee covers real-world biomarker testing and treatment patterns in resectable early-stage NSCLC.
Oncology Lung Cancer WCLC-2023

Sign up or login to unlock the full suite of MEDICALLY features
Sep 14 / Roche and Genentech
WCLC-2023-Meet the expert slides-SCLC session
Slides from the SCLC meet-the-expert session at WCLC 2023 where Stephen V. Liu covers the five-year survival data in patients with ES-SCLC treated with atezolizumab in IMpower133 based on the IMbrella A extension study results.
Oncology Lung Cancer WCLC-2023

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
Sep 27 / Springer Healthcare
Managing ROS1 fusion-positive NSCLC in Europe and the USA
Luis Paz-Ares leads Jaime Schneider and Benjamin Besse in a discussion on the management of patients with ROS1 fusion-positive NSCLC in 2022.
Oncology Non-Small Cell Lung Cancer
Bookmark this
Share page
Upcoming congresses
Access to Roche and Genentech’s latest medical information

Sign up or login to unlock the full suite of MEDICALLY features
April 25 - April 30, 2025 / Illinois, USA
AACR 2025
Oncology Lung Cancer Colorectal Cancer Gastroesophageal Cancer Solid Tumours
Subject:
American Association for Cancer Research - 116th Annual Meeting
Venue:
Medical Booth Number:
Learn More
Bookmark this
Share page

Sign up or login to unlock the full suite of MEDICALLY features
May 3 - May 6, 2025 / San Diego, USA / Virtual (Hybrid)
DDW 2025
Inflammatory Disease Inflammatory Bowel Disease
Subject:
Digestive Disease Week - 2025
Venue:
Medical Booth Number:
Notify me

Sign up or login to unlock the full suite of MEDICALLY features
View related congresses

Disease Education

The role of the Blood-Brain Barrier in lung cancer treatment

Some types of cancer, such as anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), frequently spread into the brain and central nervous system. A key challenge of treating these brain metastases is the blood-brain barrier, which you can learn more about in this video.

Watch the video
Open asset
Share page

Unleashing the T-Cell army

Watch this video that describes the cancer immunity cycle and how a tumour interacts with the human immune system.

Watch the video
Open asset
Share page

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.